Kesimpta Approved in UK as At-home Relapsing MS Therapy

Kesimpta Approved in UK as At-home Relapsing MS Therapy

292143

Kesimpta Approved in UK as At-home Relapsing MS Therapy

Kesimpta (ofatumumab) has been approved in the U.K. as the first self-administered, at-home, B-cell-targeting therapy for people with relapsing forms of multiple sclerosis (MS) and active disease. More specifically, the approval includes patients with either clinically isolated syndrome, relapsing-remitting MS (RRMS), or active secondary progressive MS (SPMS), who have been experiencing relapses or showing new lesions on MRI scans. This approval by the Medicines and Healthcare Products Regulatory Agency (MHRA) follows similar decisions in the E.U., the U.S., Canada, Switzerland,…

You must be logged in to read/download the full post.